Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes.
Villalobos CA
,
Bull P
,
Sáez P
,
Cassels BK
,
Huidobro-Toro JP
.
???displayArticle.abstract???
1. We recently described that several 2-(2,5-dimethoxy-4-substituted phenyl)ethylamines (PEAs), including 4-I=2C-I, 4-Br=2C-B, and 4-CH(3)=2C-D analogs, are partial agonists at 5-HT(2C) receptors, and show low or even negligible intrinsic efficacy at 5-HT(2A) receptors. These results raised the proposal that these drugs may act as 5-HT(2) antagonists. 2. To test this hypothesis, Xenopus laevis oocytes were microinjected with the rat clones for 5-HT(2A) or 5-HT(2C) receptors. The above-mentioned PEAs and its 4-H analog (2C-H) blocked the 5-HT-induced currents at 5-HT(2A), but not at the 5-HT(2C) receptor, revealing 5-HT(2) receptor subtype selectivity. The 5-HT(2A) receptor antagonism required a 2-min preincubation to attain maximum inhibition. 3. All PEAs tested shifted the 5-HT concentration-response curves to the right and downward. Their potencies varied with the nature of the C(4) substituent; the relative rank order of their 5-HT(2A) receptor antagonist potency was 2C-I>2C-B>2C-D>2C-H. 4. The present results demonstrate that in X. laevis oocytes, a series of 2,5-dimethoxy-4-substituted PEAs blocked the 5-HT(2A) but not the 5-HT(2C) receptor-mediated responses. As an alternative hypothesis, we suggest that the psychostimulant activity of the PEAs may not be exclusively associated with partial or full 5-HT(2A) receptor agonism.
Acuña-Castillo,
Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.
2002, Pubmed,
Xenbase
Acuña-Castillo,
Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.
2002,
Pubmed
,
Xenbase
Aghajanian,
Serotonin and hallucinogens.
1999,
Pubmed
Arvanov,
LSD and DOB: interaction with 5-HT2A receptors to inhibit NMDA receptor-mediated transmission in the rat prefrontal cortex.
1999,
Pubmed
Benloucif,
Serotonin-facilitated dopamine release in vivo: pharmacological characterization.
1993,
Pubmed
Blank,
Serotonin 5-HT2 receptor activation potentiates N-methyl-D-aspartate receptor-mediated ion currents by a protein kinase C-dependent mechanism.
1996,
Pubmed
,
Xenbase
Bonhaus,
The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.
1995,
Pubmed
Bonhaus,
RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.
1997,
Pubmed
Chambers,
Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.
2001,
Pubmed
Fiorella,
The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis.
1995,
Pubmed
Gewirtz,
Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.
2000,
Pubmed
Giroud,
2C-B: a new psychoactive phenylethylamine recently discovered in Ecstasy tablets sold on the Swiss black market.
1998,
Pubmed
Glennon,
Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity.
1992,
Pubmed
Herndon,
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
1992,
Pubmed
Kennett,
SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.
1997,
Pubmed
Krebs-Thomson,
Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors.
1998,
Pubmed
Kurrasch-Orbaugh,
Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves.
2003,
Pubmed
Kursar,
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
1994,
Pubmed
McKenna,
Differentiation of 5-hydroxytryptamine2 receptor subtypes using 125I-R-(-)2,5-dimethoxy-4-iodo-phenylisopropylamine and 3H-ketanserin.
1989,
Pubmed
Nelson,
Structure-activity relationships at 5-HT1A receptors: binding profiles and intrinsic activity.
1991,
Pubmed
Nelson,
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
1999,
Pubmed
Nichols,
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
1994,
Pubmed
Pierce,
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
1989,
Pubmed
Pierce,
Antagonist properties of d-LSD at 5-hydroxytryptamine2 receptors.
1990,
Pubmed
Pompeiano,
Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors.
1994,
Pubmed
Rabin,
5-HT2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens.
2002,
Pubmed
Sorensen,
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.
1993,
Pubmed
de Boer,
More data about the new psychoactive drug 2C-B.
1999,
Pubmed
